New analysis maps €430M in health tech investment — and points to Denmark as one of Europe’s fastest-growing ecosystems
Despite a global investment climate defined by caution, Danish health tech attracted more than €430 million in the first six months of 2026 — a 41 per cent increase compared to the same period in 2025.
The figures come from a new analysis published by Health Tech Hub Copenhagen in collaboration with Dansk Erhverv and Copenhagen Capacity. The analysis maps investment flows in the Danish health technology sector and paints a picture of an industry in substantial growth, driven by increasing international interest and a strong pipeline of emerging companies.
The largest funding rounds have gone to companies working in AI-assisted diagnostics, chronic disease management, and clinical decision support — three areas that sit squarely at the intersection of digitalisation and the existing healthcare system.
AI as infrastructure, not a feature
One of the clearest patterns in this year’s data is the shift in how investors are positioning artificial intelligence in healthcare. Whereas AI was largely treated as a feature layer on top of existing products two or three years ago, we are now seeing a growing number of companies building AI as core infrastructure — from data management and interoperability to clinical workflows.
We no longer see AI as a layer on top of health data. It is the foundation itself — and the companies that understand this are attracting capital from an entirely different calibre of investor.
This observation is shared by several of the investors Health Tech Hub Copenhagen spoke with at its bi-annual investor roundtable. What they have in common is a search for companies with strong clinical partnerships and documented outcomes — not simply technological novelty.
The regions as catalyst
Another prominent theme is the role of the Danish health regions as active partners in the commercialisation of health tech. Several of the successful funding rounds in the first half of 2026 went to companies that had already entered pilot agreements with at least one Danish region — a model that international investors value highly, because it significantly reduces clinical adoption risk.
Region Hovedstaden and Region Midtjylland have led the way with structured collaboration programmes, and there are signs that the remaining regions are following suit. For startups in hubs like HTHC, this is a decisive advantage: access to early clinical testing environments compresses the timeline from idea to clinical evidence considerably.
What happens in the second half?
Analysts are broadly optimistic, but point to two key uncertainties: the regulatory landscape in the EU — particularly the implementation of the AI Act’s requirements for high-risk applications in healthcare — and the general risk appetite among European venture capital funds, which remain selective compared to their American and Asian peers.
At Health Tech Hub Copenhagen, we continuously work to prepare our members to navigate this landscape. That means direct investor matchmaking, guidance on regulatory requirements, and access to our network of clinical partners — all with the goal of shortening the path from innovation to impact.
The full analysis is available on request from the HTHC secretariat.